FDA working with FTC on switch ads prior to approval -- FTC's Peeler says.
This article was originally published in The Tan Sheet
Executive Summary
FDA WORKING WITH FTC ON Rx-TO-OTC SWITCHES PRIOR TO APPROVAL, Federal Trade Commission Division of Advertising Practices Associate Director Lee Peeler said at a Sept. 7 Food & Drug Law Institute meeting in Washington, D.C. He noted that FDA "has already initiated a series of steps to keep us informed about the advertising issues that are likely to arise after [a] switch" and that the agency is keeping FTC informed as to which switch products are in the pipeline.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning